Status:
COMPLETED
Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
Augusta Hospital, Berlin
Conditions:
Non-small Cell Lung Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Recent studies in laboratory animals demonstrate the ability of disulfiram to significantly inhibit the growth and metastasis of a mouse model of lung cancer. Work with cells in vitro support the idea...
Detailed Description
Metastatic non small cell lung cancer remains a deadly disease with median survival times of several months. Any treatment which can prolong patients' survival without causing severe side effects is o...
Eligibility Criteria
Inclusion
- Metastatic non-small cell lung cancer
- Previously untreated
- ECOG performance status (PS) 0-1
- Liver function tests within the norm
Exclusion
- Over 18
- Willingness to abstain from alcohol
- Not pregnant
- Without a psychiatric history
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00312819
Start Date
March 1 2006
End Date
December 1 2009
Last Update
August 31 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Institute Meir Medical Center
Kfar Saba, Israel